| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jasmina Mallet, Nicolas Ramoz, Yann Le Strat, Philip Gorwood, Caroline Dubertre. Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype? European archives of psychiatry and clinical neuroscience. vol 267. issue 7. 2018-09-06. PMID:28190094. |
in a cross-sectional study, we consecutively included 61 patients with schizophrenia (34 reporting heavy cannabis use before the onset of psychosis and 27 not reporting such use), in the setting of a university hospital and a medical center. |
2018-09-06 |
2023-08-13 |
Not clear |
| M Aas, I Melle, F Bettella, S Djurovic, S Le Hellard, T Bjella, P A Ringen, T V Lagerberg, O B Smeland, I Agartz, O A Andreassen, M Tesl. Psychotic patients who used cannabis frequently before illness onset have higher genetic predisposition to schizophrenia than those who did not. Psychological medicine. vol 48. issue 1. 2018-08-06. PMID:28967348. |
psychotic patients who used cannabis frequently before illness onset have higher genetic predisposition to schizophrenia than those who did not. |
2018-08-06 |
2023-08-13 |
Not clear |
| Rami Guinguis, María Isabel Ruiz, Gabriel Rad. Is cannabidiol an effective treatment for schizophrenia? Medwave. vol 17. issue 7. 2018-05-28. PMID:28820868. |
is cannabidiol an effective treatment for schizophrenia? |
2018-05-28 |
2023-08-13 |
Not clear |
| Rami Guinguis, María Isabel Ruiz, Gabriel Rad. Is cannabidiol an effective treatment for schizophrenia? Medwave. vol 17. issue 7. 2018-05-28. PMID:28820868. |
cannabidiol has recently been proposed as an antipsychotic for schizophrenia. |
2018-05-28 |
2023-08-13 |
Not clear |
| Rami Guinguis, María Isabel Ruiz, Gabriel Rad. Is cannabidiol an effective treatment for schizophrenia? Medwave. vol 17. issue 7. 2018-05-28. PMID:28820868. |
we concluded cannabidiol probably does not improve symptoms in schizophrenia and leads to frequent side effects. |
2018-05-28 |
2023-08-13 |
Not clear |
| Guadalupe Rodríguez, Nichole M Neugebauer, Katherine Lan Yao, Herbert Y Meltzer, John G Csernansky, Hongxin Don. Δ9-tetrahydrocannabinol (Δ9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice. Pharmacology, biochemistry, and behavior. vol 159. 2018-05-21. PMID:28648819. |
the clinical onset of schizophrenia often coincides with cannabis use in adolescents and young adults. |
2018-05-21 |
2023-08-13 |
mouse |
| Ian Hamilto. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addiction (Abingdon, England). vol 112. issue 9. 2018-05-18. PMID:28419656. |
cannabis, psychosis and schizophrenia: unravelling a complex interaction. |
2018-05-18 |
2023-08-13 |
Not clear |
| Ian Hamilto. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addiction (Abingdon, England). vol 112. issue 9. 2018-05-18. PMID:28419656. |
the relationship between cannabis and psychosis and schizophrenia has tested the field of addiction for decades, and in some ways serves as measure of our ability to provide a credible contribution to public health. |
2018-05-18 |
2023-08-13 |
Not clear |
| Ian Hamilto. Cannabis, psychosis and schizophrenia: unravelling a complex interaction. Addiction (Abingdon, England). vol 112. issue 9. 2018-05-18. PMID:28419656. |
these studies provided evidence of a dose-response relationship between cannabis and psychosis, and that for those individuals with schizophrenia cannabis exacerbated their symptoms. |
2018-05-18 |
2023-08-13 |
Not clear |
| Natalia I Brzozowska, Erik J de Tonnerre, Kong M Li, Xiao Suo Wang, Aurelie A Boucher, Paul D Callaghan, Michael Kuligowski, Alex Wong, Jonathon C Arnol. The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28272498. |
cannabis use increases rates of psychotic relapse and treatment failure in schizophrenia patients. |
2018-05-16 |
2023-08-13 |
Not clear |
| Rachel A Rabin, Mera S Barr, Michelle S Goodman, Yarissa Herman, Konstantine K Zakzanis, Stephen J Kish, Michael Kiang, Gary Remington, Tony P Georg. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443616. |
effects of extended cannabis abstinence on cognitive outcomes in cannabis dependent patients with schizophrenia vs non-psychiatric controls. |
2018-05-16 |
2023-08-13 |
human |
| Rachel A Rabin, Mera S Barr, Michelle S Goodman, Yarissa Herman, Konstantine K Zakzanis, Stephen J Kish, Michael Kiang, Gary Remington, Tony P Georg. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443616. |
cross-sectional studies of the effects of cannabis on cognition in schizophrenia have produced mixed results. |
2018-05-16 |
2023-08-13 |
human |
| Rachel A Rabin, Mera S Barr, Michelle S Goodman, Yarissa Herman, Konstantine K Zakzanis, Stephen J Kish, Michael Kiang, Gary Remington, Tony P Georg. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443616. |
heavy and persistent cannabis use in schizophrenia is a common clinical problem, and effects of controlled abstinence from cannabis in these patients have not been carefully evaluated. |
2018-05-16 |
2023-08-13 |
human |
| Rachel A Rabin, Mera S Barr, Michelle S Goodman, Yarissa Herman, Konstantine K Zakzanis, Stephen J Kish, Michael Kiang, Gary Remington, Tony P Georg. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443616. |
the present study sought to determine the effects of cannabis abstinence on cognition in patients with schizophrenia and co-occurring cannabis dependence. |
2018-05-16 |
2023-08-13 |
human |
| Rachel A Rabin, Mera S Barr, Michelle S Goodman, Yarissa Herman, Konstantine K Zakzanis, Stephen J Kish, Michael Kiang, Gary Remington, Tony P Georg. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443616. |
we utilized a 28-day cannabis abstinence paradigm to investigate the state-dependent effects of cannabis on select cognitive outcomes in cannabis-dependent patients with schizophrenia and non-psychiatric controls. |
2018-05-16 |
2023-08-13 |
human |
| Rachel A Rabin, Mera S Barr, Michelle S Goodman, Yarissa Herman, Konstantine K Zakzanis, Stephen J Kish, Michael Kiang, Gary Remington, Tony P Georg. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443616. |
verbal memory and learning may improve in schizophrenia and control subjects with cannabis abstinence, but larger more definitive studies are needed. |
2018-05-16 |
2023-08-13 |
human |
| Rachel A Rabin, Mera S Barr, Michelle S Goodman, Yarissa Herman, Konstantine K Zakzanis, Stephen J Kish, Michael Kiang, Gary Remington, Tony P Georg. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 11. 2018-05-16. PMID:28443616. |
our findings underscore the importance of developing effective interventions for cannabis use disorders in schizophrenia. |
2018-05-16 |
2023-08-13 |
human |
| R M Murray, A Englund, A Abi-Dargham, D A Lewis, M Di Forti, C Davies, M Sherif, P McGuire, D C D'Souz. Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology. vol 124. 2018-05-09. PMID:28634109. |
the risk-increasing effects are not explained by shared genetic predisposition between schizophrenia and cannabis use. |
2018-05-09 |
2023-08-13 |
human |
| Uma Suryadevara, Dawn M Bruijnzeel, Meena Nuthi, Darin A Jagnarine, Rajiv Tandon, Adriaan W Bruijnzee. Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders. Current neuropharmacology. vol 15. issue 6. 2018-04-23. PMID:27804883. |
cannabis is widely used to self-medicate by older people and people with brain disorders such as amyotrophic lateral sclerosis (als), multiple sclerosis (ms), alzheimer's disease (ad), parkinson's disease (pd), bipolar disorder, and schizophrenia. |
2018-04-23 |
2023-08-13 |
Not clear |
| Gábor Nagy-Grócz, Ferenc Zádor, Szabolcs Dvorácskó, Zsuzsanna Bohár, Sándor Benyhe, Csaba Tömböly, Árpád Párdutz, László Vécse. Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine. International journal of molecular sciences. vol 18. issue 8. 2018-04-17. PMID:28758944. |
the interaction of the endocannabinoid and kynurenine system has been demonstrated to be therapeutically relevant in a number of pathological conditions, such as cannabis addiction, psychosis, schizophrenia and epilepsy. |
2018-04-17 |
2023-08-13 |
Not clear |